A Novel Hematological Inflammation-Nutrition Score (HINS) and Its Related Nomogram Model to Predict Survival Outcome in Advanced Gastric Cancer Patients Receiving First-Line Palliative Chemotherapy

Chen Chen,Zehua Wang,Yanru Qin
DOI: https://doi.org/10.2147/jir.s417798
IF: 4.5
2023-07-13
Journal of Inflammation Research
Abstract:Chen Chen, &ast Zehua Wang, &ast Yanru Qin Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yanru Qin, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Erqi District, Zhengzhou, Henan, 450052, People's Republic of China, Tel +86 13676932999, Email Purpose: This study aims to construct a novel hematological inflammation-nutrition score (HINS) and investigate its prognostic value in patients with advanced gastric cancer (AGC). We investigated the risk stratification performance of HINS and developed a HINS-based nomogram model to predict overall survival by combining traditional predictors. Patients and Methods: We conducted a retrospective study on 812 AGC patients who received first-line platinum- or fluoropyrimidine-containing chemotherapy at The First Affiliated Hospital of Zhengzhou University Hospital between 2014 and 2019. Patients were randomly divided into a training cohort (N=609) and a validation cohort (N=203). HINS (0– 2) was constructed based on a pre-chemotherapy systemic immune-inflammation index (SII) and albumin (ALB). Prognostic factors were screened by univariate and multivariate COX proportional regression models. Significant factors were used to construct a nomogram model. Internal validation was performed by calibration curves, time-dependent receiver operating characteristics (ROC) curves, and decision curve analysis (DCA), evaluating its prediction consistency, discrimination ability, and clinical net benefit. Results: HINS was constructed based on SII and ALB. HINS showed a better stratification ability than JCOG prognostic index, with significant differences between groups. Multivariate analysis showed that ECOG ≥ 1 (HR: 1.379; P=0.005), Stage IV (HR: 1.581; P < 0.001), diffuse-type histology (HR: 1.586; P < 0.001), number of metastases ≥ 2 (HR: 1.274; P=0.038), without prior gastrectomy (HR: 1.830; P < 0.001), ALP ≥ULN (HR: 1.335; P=0.034), HINS (P < 0.001) were independent factors of OS. We successfully established a HINS-based nomogram model that showed a strong discriminative ability, accuracy, and clinical utility in training and validation cohorts. Conclusion: HINS shows a superior risk stratification ability, which might be a potential prognostic biomarker for AGC patients receiving palliative first-line palliative chemotherapy. The HINS-based nomogram model is a convenient and efficient tool for managing prognosis and follow-up treatments. Keywords: hematological inflammation-nutrition score, nomogram model, advanced gastric cancer, prognosis Gastric carcinoma (GC) is one of the most common malignancies and the fourth leading cause of cancer-related death worldwide. 1 The global average annual incidence of GC was approximately 1806,000 cases, while Asia accounted for 689,000 cases (77.4%). 1 Palliative chemotherapy remains the standard care of metastatic or recurrent GC, with the combination of fluoropyrimidine and platinum analog as the first-line treatment. 2 Despite great breakthroughs in second- or late-line therapeutic options, the median survival time of advanced gastric carcinoma (AGC) patients was merely 15 months. 3,4 Thus, precise prediction of individual prognosis of AGC patients is strongly warranted. Previous studies have identified several clinicopathological indicators to predict prognosis of AGC patients. The Japan Clinical Oncology Group (JCOG) prognostic index, including Eastern Cooperative Oncology Group (ECOG) performance status (PS), primary tumor resection, number of metastases, and serum alkaline phosphatase (ALP) level, was one of the most robust prognostic scoring systems based on JCOG 9912 trial involving 760 patients. 5 Moreover, the SPIRITS and G-SOX trials have externally validated the excellent stratification of JCOG prognostic index. 6–8 Notably, its clinical applicability still lacks enough real-world data validation since it is originally constructed based on enrolling appropriate patients into clinical trials. 9 The American Joint Committee on Cancer (AJCC) staging system is also widely applied by physicians to predict prognoses. However, patients with the same TNM stage may vary in survival. It is necessary to improve prediction accuracy by incorporating other indicators. Systemic inflammation response plays a vital role in tumorigenesis. 10 There is a complex interplay between the tumor microenvironment and cancer-related inflammation. Recently, elements of the complete blood count (CBC), either alone or in combination, have been -Abstract Truncated-
immunology
What problem does this paper attempt to address?